{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:49:38Z","timestamp":1772628578812,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Direct evidence for persistence of Mycobacterium tuberculosis (Mtb) during asymptomatic latent tuberculosis infection (LTBI) in humans is currently lacking. Moreover, although a 12-week regimen of once-weekly isoniazid and rifapentine (3HP) is currently recommended by the CDC as treatment for LTBI, experimental evidence for 3HP-mediated clearance of persistent Mtb infection in human lungs has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Using a nonhuman primate (NHP) model of TB, we sought to assess 3HP treatment\u2013mediated clearance of Mtb infection in latently infected macaques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixteen NHPs were infected via inhalation with \u223c10 cfu of Mtb CDC1551, after which asymptomatic animals were either treated with 3HP or left untreated. Pharmacokinetics of the 3HP regimen were measured. Following treatment, animals were coinfected with simian immunodeficiency virus to assess reactivation of LTBI and development of active TB disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Fourteen NHPs remained free of clinical signs or microbiological evidence of active TB following infection with Mtb and were subsequently either treated with 3HP (n\u2009=\u20097) or left untreated (n\u2009=\u20097). Untreated NHPs were asymptomatic for 7 months but harbored persistent Mtb infection, as shown by reactivation of latent infection following simian immunodeficiency virus coinfection. However, none of the treated animals developed TB reactivation disease, and they remained without clinical or microbiological evidence of persistent bacilli, suggesting treatment-mediated clearance of bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mtb can persist in asymptomatic macaques for at least 7 months. Furthermore, 3HP treatment effectively cleared bacteria and prevented reactivation of TB in latently infected macaques.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201903-0646oc","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T18:34:59Z","timestamp":1571942099000},"page":"469-477","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":14,"title":["Isoniazid and Rifapentine Treatment Eradicates Persistent\n                    <i>Mycobacterium tuberculosis<\/i>\n                    in Macaques"],"prefix":"10.1093","volume":"201","author":[{"given":"Taylor W.","family":"Foreman","sequence":"first","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison N.","family":"Buc\u015fan","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smriti","family":"Mehra","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida College of Pharmacy, Gainesville, Florida"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara A.","family":"Doyle","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasi","family":"Russell-Lodrigue","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel R.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Altman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology and"},{"name":"Emory Vaccine Center and Yerkes National Primate Center, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl L.","family":"Day","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology and"},{"name":"Emory Vaccine Center and Yerkes National Primate Center, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel D.","family":"Ernst","sequence":"additional","affiliation":[{"name":"Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry M.","family":"Blumberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-4705","authenticated-orcid":false,"given":"Jyothi","family":"Rengarajan","sequence":"additional","affiliation":[{"name":"Emory Vaccine Center and Yerkes National Primate Center, Emory University, Atlanta, Georgia"},{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-1257","authenticated-orcid":false,"given":"Deepak","family":"Kaushal","sequence":"additional","affiliation":[{"name":"Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana"},{"name":"Southwest National Primate Research Center, Texas Biomedical Research Center, San Antonio, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"key":"2026030321413621700_bib1","article-title":"Global Tuberculosis Report","author":"Global Tuberculosis Programme","year":"2018"},{"key":"2026030321413621700_bib2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med"},{"key":"2026030321413621700_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJM199201233260404","article-title":"An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms","volume":"326","author":"Daley","year":"1992","journal-title":"N Engl J Med"},{"key":"2026030321413621700_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026030321413621700_bib5","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026030321413621700_bib6","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"2026030321413621700_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ilar\/ilx015","article-title":"Translational research in the nonhuman primate model of tuberculosis","volume":"58","author":"Foreman","year":"2017","journal-title":"ILAR J"},{"key":"2026030321413621700_bib8","doi-asserted-by":"crossref","first-page":"E5636","DOI":"10.1073\/pnas.1611987113","article-title":"CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection","volume":"113","author":"Foreman","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321413621700_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0684.2012.00536.x","article-title":"The non-human primate model of tuberculosis","volume":"41","author":"Kaushal","year":"2012","journal-title":"J Med Primatol"},{"key":"2026030321413621700_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trivac.2014.02.001","article-title":"Humoral and lung immune responses to Mycobacterium tuberculosis infection in a primate model of protection","volume":"3","author":"Dutta","year":"2014","journal-title":"Trials Vaccinol"},{"key":"2026030321413621700_bib11","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1038\/ncomms9533","article-title":"Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis","volume":"6","author":"Kaushal","year":"2015","journal-title":"Nat Commun"},{"key":"2026030321413621700_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0684.2011.00485.x","article-title":"Reactivation of latent tuberculosis in rhesus macaques by coinfection with simian immunodeficiency virus","volume":"40","author":"Mehra","year":"2011","journal-title":"J Med Primatol"},{"key":"2026030321413621700_bib13","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/infdis\/jix625","article-title":"High turnover of tissue macrophages contributes to tuberculosis reactivation in simian immunodeficiency virus-infected rhesus macaques","volume":"217","author":"Kuroda","year":"2018","journal-title":"J Infect Dis"},{"key":"2026030321413621700_bib14","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.celrep.2019.01.021","article-title":"HIV-1 and SIV infection are associated with early loss of lung interstitial CD4+ T cells and dissemination of pulmonary tuberculosis","volume":"26","author":"Corleis","year":"2019","journal-title":"Cell Reports"},{"key":"2026030321413621700_bib15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321413621700_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/jpids\/pit077","article-title":"Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection","volume":"3","author":"Weiner","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026030321413621700_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2026030321413621700_bib18","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1128\/AAC.41.12.2670","article-title":"Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide","volume":"41","author":"Peloquin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321413621700_bib19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1164\/rccm.201408-1502OC","article-title":"The DosR regulon modulates adaptive immunity and is essential for Mycobacterium tuberculosis persistence","volume":"191","author":"Mehra","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321413621700_bib20","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1073\/pnas.1711373114","article-title":"In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis","volume":"115","author":"Gautam","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026030321413621700_bib21","doi-asserted-by":"crossref","first-page":"L731","DOI":"10.1152\/ajplung.00120.2011","article-title":"Stereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with Mycobacterium tuberculosis","volume":"301","author":"Luciw","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2026030321413621700_bib22","first-page":"712","article-title":"CXCR5+ T helper cells mediate protective immunity against tuberculosis","volume":"123","author":"Slight","year":"2013","journal-title":"J Clin Invest"},{"key":"2026030321413621700_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026030321413621700_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.tim.2017.08.001","article-title":"Opening Pandora\u2019s box: mechanisms of Mycobacterium tuberculosis resuscitation","volume":"26","author":"Veatch","year":"2018","journal-title":"Trends Microbiol"},{"key":"2026030321413621700_bib25","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.4049\/jimmunol.1800993","article-title":"The end of the binary era: revisiting the spectrum of tuberculosis","volume":"201","author":"Lin","year":"2018","journal-title":"J Immunol"},{"key":"2026030321413621700_bib26","doi-asserted-by":"crossref","first-page":"e1005739","DOI":"10.1371\/journal.ppat.1005739","article-title":"PET CT identifies reactivation risk in cynomolgus macaques with latent M. tuberculosis","volume":"12","author":"Lin","year":"2016","journal-title":"PLoS Pathog"},{"key":"2026030321413621700_bib27","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tim.2017.03.007","article-title":"Integrating lung physiology, immunology, and tuberculosis","volume":"25","author":"Torrelles","year":"2017","journal-title":"Trends Microbiol"},{"key":"2026030321413621700_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026030321413621700_bib29","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/S1473-3099(18)30111-7","article-title":"Tuberculosis: advances and challenges in development of new diagnostics and biomarkers","volume":"18","author":"Walzl","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026030321413621700_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0039-2016","article-title":"Treatment of latent tuberculosis infection","volume":"5","author":"Haley","year":"2017","journal-title":"Microbiol Spectr"},{"key":"2026030321413621700_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2026030321413621700_bib32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/cid\/cix505","article-title":"High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent Mycobacterium tuberculosis infection","volume":"65","author":"Sandul","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026030321413621700_bib33","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union against Tuberculosis Committee on Prophylaxis","volume":"60","author":"Thompson","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2026030321413621700_bib34","doi-asserted-by":"crossref","first-page":"k2738","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1164\/rccm.v203retraction1","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"record-id":"27524"},{"DOI":"10.1164\/rccm.v203retraction1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000}}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/4\/469\/67179042\/ajrccm_201_4_469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/201\/4\/469\/67179042\/ajrccm_201_4_469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:41:46Z","timestamp":1772592106000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/201\/4\/469\/8496461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,15]]},"published-print":{"date-parts":[[2020,2,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201903-0646oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"2019-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}